Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
AssigneeAxial Biotherapeutics, Inc.
InventorsAnthony Stewart Campbell, David H. Donabedian
Life of this patent
Estimating the term…
Abstract
The present disclosure describes methods and compositions for the treatment of neurological disorders and related symptoms by the in vivo sequestration and excretion of microbial metabolites. These metabolites are related to neurological disorders such as autism and Parkinson's disease, as well as intestinal hyperpermeability (leaky gut) and gastrointestinal comorbidities associated with such disorders.
Claims25
-14. (canceled)
A sequestrant composition for use in the treatment of a subject having a behavioral symptom of a neurological disorder associated with intestinal hyperpermeability or intestinal dysbiosis, comprising:
- a multiplicity of biocompatible particles and/or polymers which are non-absorbable by the digestive tract of the subject,
- wherein the sequestrant composition binds to at least a fraction of at least one intestinal metabolite present in the digestive tract of the subject to form a sequestrant-metabolite complex, such that the sequestrant-metabolite complex is eliminated from the digestive tract, and
- wherein the intestinal metabolite is associated with the development or presence of the behavioral symptom.
(canceled)
A method of treating a subject having a behavioral symptom of a neurological disorder associated with intestinal hyperpermeability or intestinal dysbiosis, comprising:
- administering to said subject a sequestrant composition which binds to at least a fraction of at least one intestinal metabolite present in the digestive tract of the subject to form a sequestrant-metabolite complex, such that the sequestrant-metabolite complex is eliminated from the digestive tract;
- wherein the intestinal metabolite is associated with the development or presence of the behavioral symptom, and
- wherein the sequestrant composition comprises a multiplicity of biocompatible particles which are non-absorbable by the digestive tract of the subject.
(canceled)
(canceled)
(canceled)
A method of reducing the amount of one or more intestinal metabolites from a subject having a behavioral symptom of a neurological disorder associated with intestinal hyperpermeability or intestinal dysbiosis, comprising:
- administering to said subject a sequestrant composition which binds to at least a fraction of at least one intestinal metabolite present in the digestive tract of the subject to form a sequestrant-metabolite complex, such that the sequestrant-metabolite complex is eliminated from the digestive tract;
- wherein the intestinal metabolite is associated with the development or presence of the behavioral symptom, and
- wherein the sequestrant composition comprises a multiplicity of biocompatible particles which are non-absorbable by the digestive tract of the subject.
Dependencies are inferred from the claim text.